Apoptotic index correlates to bcl-2 and p53 protein expression, histological grade and prognosis in invasive breast cancers

Anticancer Research

Volumn 18, Issue 3 B, 1998, Pages 1989-1997

  Zhang, Guo Jun ^a   Kimijima, Izo ^a   Abe, Rikiya ^a   Watanabe, Takanori ^a   Kanno, Masahiko ^a   Hara, Kiyoshi ^a   Tsuchiya, Atsuo ^a  

^a FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Apoptosis; Apoptotic index; bc1 2; Breast cancer; p53; Prognostic factor

Indexed keywords

PROTEIN BCL 2; PROTEIN P53;

ADULT; AGED; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER GRADING; CANCER STAGING; CANCER SURVIVAL; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MICROSCOPY; MITOSIS INDEX; PATHOLOGY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

EID: 0031927561     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Wyllie AH, Morris RG, Smith AL, Dunlop D: Chromatin cleavage in apoptosis: association with condensed chromatin morphology and dependence on macromolecular synthesis. J Pathol 142: 67-77, 1984.
2. Wyllie AH: The biology of cell death in tumours. Anticancer Res 5: 131-136, 1985.
3. Lipponen P, Aaltomaa S, Kosma VM, Syrjanen K: Apoptosis in breast cancer as related to histopathological characteristics and prognosis. Eur J Cancer 30A: 2068-2073, 1994.
4. Lipponen PK, Aaltomaa S: Apoptosis in bladder cancer as related to standard prognostic factors and prognosis. J Pathol 173: 333-339, 1994.
5. Heatley MK: Association between the apoptotic index and established prognostic parameters in endometrial adenocarcinoma. Histopathology 27: 469-472, 1995.
6. Tatebe S, Ishida M, Kasagi N, Tsujitani S, Kaibara N, Ito H: Apoptosis occurs more frequently in metastatic foci than in primary lesions of human colorectal carcinomas: analysis by terminal-deoxynucleotidyl-transferase-mediated dUTP-biotin nick end labeling. Int J Cancer 65: 173-177, 1996.
7. Reed JC: Bcl-2 and the regulation of programmed cell death. J Cell Biol 124: 1-6, 1994.
8. Gee JM, Robertson JF, Ellis IO, Willsher P, McClelland RA, Hoyle HB, Kyme SR, Finlay P, Blamey RW, Nicholson RI: Immunocytochemical localization of BCL-2 protein in human breast cancers and its relationship to a series of prognostic markers and response to endocrine therapy. Int J Cancer 59: 619-628, 1994.
9. Silvestrini R, Veneroni S, Daidone MG, Benini E, Boracchi P, Mezzetti M, Di Fronzo G, Rilke F, Veronesi U: The Bcl-2 protein: a prognostic indicator strongly related to pS3 protein in lymph node-negative breast cancer patients. J Natl Cancer Inst 86: 499-504, 1994.
10. Moll UM, LaQuaglia M, Benard J, Riou G: Wild-type p53 protein undergoes cytoplasmic sequestration in undifferentiated neuroblastomas but not in differentiated tumors. Proc Natl Acad Sci USA 92: 4407-4411, 1995.
11. Malcomson RD, Oren M, Wyllie AH, Harrison DJ: p53-independent death and p53-induced protection against apoptosis in fibroblasts treated with chemotherapeutic drugs. Br J Cancer 72: 952-957, 1995.
12. Runnebaum IB, Yee JK, Kieback DG, Sukumar S, Friedmann T: Wild-type p53 suppresses the malignant phenotype in breast cancer cells containing mutant p53 alleles. Anticancer Res 14: 1137-1144, 1994.
13. Silvestrini R, Benini E, Daidone MG, Veneroni S, Boracchi P, Cappelletti V, Di Fronzo G, Veronesi U: p53 as an independent prognostic marker in lymph node-negative breast cancer patients. J Natl Cancer Inst 85: 965-970, 1993.
14. Friedrichs K, Gluba S, Eidtmann H, Jonat W: Overexpression of p53 and prognosis in breast cancer. Cancer 72: 3641-3647, 1993.
15. Hartmann A, Blaszyk H, Saitoh S, Tsushima K, Tamura Y, Cunningham JM, McGovem RM, Schroeder JJ, Sommer SS, Kovach JS: High frequency of p53 gene mutations in primary breast cancers in Japanese women, a low-incidence population. Br J Cancer 73: 896-901, 1996.
16. Joensuu H, Pylkkanen L, Toikkanen S: Bcl-2 protein expression and long-term survival in breast cancer. Am J Pathol 145: 1191-1198, 1994.
17. Silvestrini R, Benini E, Veneroni S, Daidone MG, Tomasic G, Squicciarini P, Salvadori B: p53 and bcl-2 expression correlates with clinical outcome in a series of node-positive breast cancer patients. J Clin Oncol 14: 1604-1610, 1996.
18. Wyllie AH, Beattie GJ, Hargreaves AD: Chromatin changes in apoptosis. Histochem J 13: 681-692, 1981.
19. Wyllie AH: What is apoptosis? Histopathology 10: 995-998, 1986.
20. Tsuda H, Hirohashi S, Shimosato Y, Hirota T, Tsugane S, Watanabe S, Terada M, Yamamoto H: Correlation between histologic grade of malignancy and copy number of c-erbB-2 gene in breast carcinoma. A retrospective analysis of 176 cases. Cancer 65: 1794-1800, 1990.
21. van Slooten HJ, Clahsen PC, van Dierendonck JH, Duval C, Pallud C, Mandard AM, Delobelle-Deroide A, van de Velde CJ, van de Vijver MJ: Expression of Bcl-2 in node-negative breast cancer is associated with various prognostic factors, but does not predict response to one course of perioperative chemotherapy. Br J Cancer 74: 78-85, 1996.
22. Kaplan E, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 58: 457-481, 1958.
23. Cox O: Regression models and life tables. J R Stat Soc Britain 32: 187-220, 1972.
24. Bargou RC, Daniel PT, Mapara MY, Bommert K, Wagener C, Kallinich B, Royer HD, Dorken B: Expression of the bcl-2 gene family in normal and malignant breast tissue: low bax-alpha expression in tumor cells correlates with resistance towards apoptosis. Int J Cancer 60: 854-859, 1995.
25. Leek RD, Kaklamanis L, Pezzella F, Gatter KC, Harris AL: bcl-2 in normal human breast and carcinoma, association with oestrogen receptor-positive, epidermal growth factor receptor-negative tumours and in situ cancer. Br J Cancer 69: 135-139, 1994.
26. Nathan B, Gusterson B, Jadayel D, O'Hare M, Anbazhagan R, Jayatilake H, Ebbs S, Micklem K, Price K, Gelber R, et al: Expression of BCL-2 in primary breast cancer and its correlation with tumour phenotype. For the International (Ludwig) Breast Cancer Study Group. Ann Oncol 5: 409-414, 1994.
27. Brady HJM, Gil-Gomez G, Kirberg J, Berns AJM: Baxa perturbs T cell development and affects cell cycle entry of T cells. EMBO J 15: 6991-7001, 1996.
28. O'Reilly LA, Huang DC, Strasser A: The cell death inhibitor Bcl-2 and its homologues influence control of cell cycle entry. EMBO J 15: 6979-6990, 1996.
29. Miyashita T, Krajewski S, Krajewska M, Wang HG, Lin HK, Liebermann DA, Hoffman B, Reed JC: Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 9: 1799-1805, 1994.
30. Miyashita T, Reed JC: Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80: 293-299, 1995.
31. Isola J, Visakorpi T, Holli K, Kallioniemi OP: Association of overexpression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients. J Natl Cancer Inst 84: 1109-1114, 1992.
32. Barbareschi M, Caffo O, Veronese S, Leek RD, Fina P, Fox S, Bonzanini M, Girlando S, Morelli L, Eccher C, Pezzella F, Doglioni C, Dalla Palma P, Harris A: Bcl-2 and p53 expression in node-negative breast carcinoma: a study with long-term follow-up. Hum Pathol 27: 1149-1155, 1996.
33. Zhang G, Tsuda H, Adachi I, Fukutomi T, Yamamoto H, Hirohashi S: Value of cancer-related oncoprotein expression as prognostic factors in breast-cancer with one to three axillary lymph nodes positive. Gan To Kagaku Ryoho 23: 66-74, 1996.
34. Haldar S, Negrini M, Monne M, Sabbioni S, Croce CM: Down-regulation of bcl-2 by p53 in breast cancer cells. Cancer Res 54: 2095-2097, 1994.
35. Boise LH, Gonzalez-Garcia M, Postema CE, Ding L, Lindsten T, Turka LA, Mao X, Nunez G, Thompson CB: bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell 74: 597-608, 1993.
36. Reynolds JE, Yang T, Qian L, Jenkinson JD, Zhou P, Eastman A, Craig RW: Mcl-1, a member of the Bcl-2 family, delays apoptosis induced by c-Myc overexpression in Chinese hamster ovary cells. Cancer Res 54: 6348-6352, 1994.
37. Korsmeyer SJ, Shutter JR, Veis DJ, Merry DE, Oltvai ZN: Bcl-2/Bax: a rheostat that regulates an anti-oxidant pathway and cell death. [Review] [34 refs]. Semin Cancer Biol 4: 327-332, 1993.
38. Zha H, Aime-Sempe C, Sato T, Reed JC: Proapoptotic protein Bax heterodimerizes with Bcl-2 and homodimerizes with Bax via a novel domain (BH3) distinct from BH1 and BH2. J Biol Chem 277: 7440-7444, 1996.
39. Yang E, Zha J, Jockel J, Boise LH, Thompson CB, Korsmeyer SJ: Bad, a heterodimeric partner for Bcl-XL and Bcl-2, displaces Bax and promotes cell death. Cell 80: 285-291, 1995.
40. Kiefer MC, Brauer MJ, Powers VC, Wu JJ, Umansky SR, Tomei LD, Barr PJ: Modulation of apoptosis by the widely distributed Bcl-2 homologue Bak. Nature 374: 736-739, 1995.
41. Krajewski S, Blomqvist C, Franssila K, Krajewska M, Wasenius VM, Niskanen E, Nordling S, Reed JC: Reduced expression of proapoptotic gene BAX is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma. Cancer Res 55: 4471-4478, 1995.
42. Krajewska M, Moss SF, Krajewski S, Song K, Holt PR, Reed JC: Elevated expression of Bcl-X and reduced Bak in primary colorectal adenocarcinomas. Cancer Res 56: 2422-2427, 1996.